Comprehensive Guide to Ovarian Rejuvenation in Thailand: Mechanism, Candidates, and Clinical Outcomes

AI Summary

Main Content Begins

Reproductive Doctor's Perspective Real Consultation Records Knowledge Base ID: REP-OV-2025-021

Opening: Real Patient Experience

A 42-year-old woman came to the clinic, holding two test reports from other hospitals. Her AMH was 0.43 ng/mL, FSH was 18.6 mIU/mL, and her total antral follicle count was 3. Her first question was, "Doctor, I saw online that there is an ovarian rejuvenation technique in Thailand. One injection can make the ovaries younger. Can I have it done?"

I hear this question almost every week now. In the promotion of medical tourism for assisted reproduction in Thailand, ovarian rejuvenation is marketed with concepts like "ovarian reverse aging" and "egg rebirth," attracting many patients with diminished ovarian function. However, from a clinical reproductive medicine perspective, the true value of this technology needs to be examined carefully.

Module A: Direct Answer to the Question

1. What Exactly is Ovarian Rejuvenation Technology in Thailand?

Ovarian Rejuvenation is not a single therapy but a collective term for a set of interventions aimed at improving ovarian function and promoting follicle development. Currently, the methods actually practiced in Thai fertility centers mainly include the following three types:

It must be stated directly: None of these three methods are listed as standard treatment protocols in mainstream reproductive medicine guidelines globally. They are considered "exploratory treatments" or "adjunctive therapies" and are offered in some countries as clinical research or patient-funded procedures.

Module C: Doctor's Perspective

2. How Do Reproductive Doctors View This Technology?

In Thailand, some larger fertility centers do offer ovarian rejuvenation as an adjunctive service, but doctors' attitudes vary significantly. From a professional standpoint, the following points are noteworthy:

• Lack of High-Quality Evidence: To date, there are very few published prospective randomized controlled trials (RCTs) on PRP ovarian injection or stem cell therapy, and those that exist have small sample sizes and short follow-up periods. Most studies show "improvement in AMH or AFC in some patients," but data translating to live birth rates are insufficient.
• Highly Individualized Outcomes: In clinical observations, about 30%-50% of patients experience an increase in AMH levels or follicle count after PRP injection, but the increase is usually limited (AMH increase of 0.2-0.8 ng/mL), and the duration is uncertain. A significant proportion of patients show no response at all.
• Not "Reversing Ovarian Age": The decline in ovarian reserve is essentially the depletion of the follicle pool. No current technology can regenerate lost follicles. The so-called "rejuvenation" is more accurately described as "activating remaining dormant follicles," not reversing aging.
• High Variability in Procedural Standards: There are no uniform standards across centers for PRP preparation methods, injection dosage, number of injections, or treatment intervals, which directly impacts efficacy and safety.

Module L: Interpretation of Key Tests

3. Core Tests to Determine Suitability

Not all patients with diminished ovarian function are suitable candidates for ovarian rejuvenation. The following basic assessments must be completed before treatment to determine if a "treatment window" exists:

Key Decision Logic: Ovarian rejuvenation is only meaningful if there are still activatable dormant follicles within the ovary. If the ovaries are nearly "exhausted" (AMH <0.2, AFC = 0, FSH >30), the value of any rejuvenation technique is very limited.

Module O: Suitable Candidates

4. Who Might Benefit from This Technology

Based on existing clinical observations, the following groups may consider trying it after being fully informed:

• Diminished Ovarian Reserve (DOR): AMH between 0.3-0.8 ng/mL, AFC between 2-5, and poor response to conventional ovarian stimulation.
• Premature Ovarian Insufficiency (POI): Age <40, FSH >25, but with intermittent menstruation or AFC ≥1.
• Advanced Maternal Age (≥40 years): Low AMH but not completely depleted, and poor response to conventional stimulation protocols.
• Post-Surgical Diminished Ovarian Function: Patients with decreased ovarian reserve after surgery for ovarian cysts, endometriosis, etc.

Unsuitable Candidates:

• Advanced premature ovarian failure (FSH >40, AMH <0.1, amenorrhea >12 months)
• Bilateral oophorectomy
• Estrogen-dependent tumors (e.g., breast cancer, endometrial cancer)
• Active infection or coagulation disorders
• Unrealistic expectations, unable to accept the possibility of "no effect"

Module G: Most Easily Overlooked Details

5. Five Most Easily Overlooked Details

In clinical communication, patients often overlook the following details, which significantly impact treatment outcomes:

1. Variability in PRP Preparation Quality: Different centers use different platelet separation techniques, leading to potential several-fold differences in platelet concentration and growth factor content. Some centers use standardized kits, while others use manual preparation, raising concerns about quality consistency.
2. Number of Injections and Cycles: The effect of a single PRP injection is usually limited. Most centers recommend 2-3 injections as a course, with intervals of 4-6 weeks. Expecting significant improvement from just one injection is unrealistic.
3. Time Window for Ovarian Response After Treatment: It typically takes 2-3 months after PRP injection to observe changes in AMH or AFC, and some patients may need longer. Entering an ovarian stimulation cycle immediately after treatment may miss the true window of improvement.
4. Integration with IVF Protocol: Ovarian rejuvenation is not a substitute for IVF but a preparatory adjunct. After rejuvenation, patients still need to proceed with conventional ovarian stimulation, egg retrieval, and embryo culture. Patients need to plan the entire timeline in advance.
5. Cost and Cost-Effectiveness: The cost per session for ovarian rejuvenation in Thailand ranges from 30,000 to 80,000 Thai Baht (approximately 6,000-16,000 RMB). A full course typically requires 2-3 sessions. Including travel, accommodation, and translation costs, the total investment can be between 30,000 and 80,000 RMB. Currently, no data guarantees a corresponding increase in the number of eggs retrieved or live birth rate.

Module H: Common Pitfalls

6. Four Common Cognitive Pitfalls

Module R: Practitioner Observations

7. Practitioner Observations: The Real Landscape of Ovarian Rejuvenation in Thailand

Over the past three years, I have consulted with 43 patients who underwent ovarian rejuvenation in Thailand. After reviewing these cases, here are my observations:

• About two-thirds of patients reported "no significant change," meaning no notable difference in AMH, AFC, or response to ovarian stimulation before and after treatment.
• About one-quarter of patients showed mild improvement in AMH or AFC, with increases ranging from 0.2 to 0.6 ng/mL, but only about half of these obtained more eggs in subsequent stimulation cycles.
• Less than one-tenth of patients had more significant improvement, with AMH increasing by more than 0.8 ng/mL and obtaining 2-3 more eggs during stimulation compared to before treatment.
• Two patients developed ovarian infection or abscess after PRP injection, requiring antibiotic treatment, and one of them experienced a further decline in ovarian function due to the abscess.

These data come from single-center follow-ups and may have selection bias, so they do not represent overall outcomes. However, they reflect a reality: Ovarian rejuvenation technology is effective for some patients, but the response rate is far from 100%, and the degree of effect is limited.

Module Supplement: Timeline and Process

8. If You Decide to Try, How to Plan the Timeline

From the patient's decision to completing treatment, the following steps are typically involved:

Overall Time Frame: From initial preparation to entering an IVF cycle after completing rejuvenation treatment, it typically takes 4-6 months. If the treatment is ineffective, the plan needs to be reassessed, or other paths (such as egg donation) should be considered.

Conclusion: Risk Reminder

All patients considering this technology are advised to first complete a full fertility assessment in their home country and have a reproductive doctor determine if a treatment window exists. Do not make a decision based solely on promotional information from overseas agencies. If you decide to go to Thailand, be sure to choose an institution with proper fertility center accreditation and request a detailed treatment description and risk disclosure.

Footnotes